Skip to main
NUVL

Nuvalent (NUVL) Stock Forecast & Price Target

Nuvalent (NUVL) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 47%
Buy 53%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nuvalent Inc is positioned favorably in the oncology market with its product candidates NVL-520 and NVL-655 showing deep and durable antitumor responses alongside improved tolerability, which may enhance their potential to capture a significant share of the oncogene-driven non-small cell lung cancer (NSCLC) market, projected to exceed $3.6 billion in peak revenue. The company also benefits from favorable comparative metrics against established treatments, with potential upside owing to advances in ROS1 detection techniques that could expand the patient population eligible for its therapies. Additionally, NVL-330, a CNS-friendly HER2 inhibitor, is supported by promising preclinical data, suggesting that it could enhance treatment duration and patient compliance, further reinforcing a positive outlook for the company's overall market positioning and revenue growth.

Bears say

Nuvalent Inc is facing significant challenges that could hinder its financial performance and future growth prospects. Key concerns include potential safety signals from product candidates, which may compromise regulatory approval and limit competitive positioning, alongside the risk of negative trial readouts that could delay commercialization. Additionally, there are significant worries regarding slower-than-expected trial enrollment, adverse regulatory decisions, and challenges in securing adequate capital for research, all of which contribute to a negative outlook for the company's stock.

Nuvalent (NUVL) has been analyzed by 15 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 53% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvalent (NUVL) Forecast

Analysts have given Nuvalent (NUVL) a Buy based on their latest research and market trends.

According to 15 analysts, Nuvalent (NUVL) has a Buy consensus rating as of Jan 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $135, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $135, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvalent (NUVL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.